A Randomized, Delayed-Treatment Controlled, Phase 2 Pilot Study of Manualized MDMA-Assisted Therapy for Young Adults with Chronic Treatment-Resistant Major Depressive Disorder

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520319-42-01

Enrollment

Registered

2026-07-03

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

Recruitment and retention, Moderate to severe adverse events, Adverse event of special interest and Serious adverse events

Detailed description

Between-group difference in depression severity, Between-group difference in functional impairment severity

Interventions

DRUGMidomafetamine

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Recruitment and retention, Moderate to severe adverse events, Adverse event of special interest and Serious adverse events	—

Secondary

Measure	Time frame
Between-group difference in depression severity, Between-group difference in functional impairment severity	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 4, 2026